

Dimerization Effects in MAPK cascade

Paweł Kocieniewski

MAPK Core Architecture







Function

- Responsible for transducing signals induced by
 - ERK1/2 mitogens (growth factors)
 - JNK/p38 heat shock, UV, osmotic stress
 - ERK 5 responsible for cardiovascular development

MAPK Cascade



The Mechanism of Transduction




MAPKKK: A-Raf, B-Raf, C-Raf

MAPKK: MEK1/2


MAPK: ERK1/2

Scaffolds in MAPK Signalling




Key Dynamics I


1) Ultrasensitivity ('non-linearity'): graded input -> "digital response"




2) Transient vs. sustained response (negative feedback)

Output/Effect Relationship







ERK1/2 Cascade

- MAPKKK A-Raf, B-Raf, C-Raf
- MAPKK MEK1/2
- MAPK ERK1/2
- Intensively investigated because of its involvement in cancer

Involvement in Human Disease

1) Involvement in Malignancies: RAS mutations in 15% of cancers, ERK upregulated in 30%


- 2) B-Raf Mutatations:
- melanoma (30–60%), thyroid cancer (30–50%)
- colorectal cancer (5–20%) and
- ovarian cancer (~30%)
- others (1–3%)

Publication Statistics

- 1) RAS 40154/5734
- 2) RAF 8515/962
- 3) MEK 7435/353
- 4) Erk 20087/927
- 5) KRS 153/7
- 6) IMP-51/7

RAF Regulation


- 1. N-terminal autoinhibitory domain
- 2. C-terminal catalytic domain
- 3. All Raf proteins require dimerization, phosphorylation, and membrane recruitment for full activation



Differences between B-Raf and C-RAF

- 1. B-Raf Activation: requires only activation segment phosphorylation (T598, S601)
- 2. C-Raf Activation: activation segment (T491,S494), additionally S338 and T341
- 3. A-Raf follows a pattern similar to C-Raf


RAF Isoforms



Dimerization in MAPK

- RAS dimerization at the membrane
- RAF promoted by RAS and KSR
- MEK one isoform represses the other
- Erk distinct signalling roles

Raf Dimers





- 1. Homodimers
 - forced dimerization results in activation
 - unclear mechanism side-to-side dimerization
- 2. Heterodimer far more active than homodimers/monomers (50x-100x)
- 3. Play role in cancers / B-Raf Inhibitor Paradox

Raf Heterodimer


- Induced by RAS activation
- Negatively Regulated by Erk phosphorylation
- In certain cancers, mutant B-Raf constitutively binds and activates C-Raf
- Protomers in a dimer can transactivate each other – not certain if it is due to phosphorylation or conformation change

Raf Heterodimer Signalling






Raf Inhibitor Paradox





KSR Dimerization

- 1. Inhibited by IMP
- 2. Upon Ras-Induced IMP1 Degradation dimerizes
- 3. KSR dimerization may promote Raf Dimerization



MEK1/2 Heterodimer






- 1. Mek1 decreases the activity of Mek2
- 2. Without Mek1, Mek2 activation is slighlty elevated but prolonged
- 3. Erk phosphorylation of Thr292 is required for both Mek1 and Mek2 attenuation
- 4. This mode of regulation is mediated via Mek1/2 heterodimerization


Erk Dimers

- Upon activation Erk1 and Erk2 homodimerize (Erk1/2 heterodimer is unstable)
- 2. Dimers enter nucleus via active transport while monomers enter passively
- 2. Monomers activate nuclear substrates
- 3. Dimers phosphorylate cytoplasmic targets
- 4. Perhaps dimers anchor Erk in the cytoplasm


Key Dynamics II




Modelling Efforts – Selected Models




Brightman & Fell 2000



Schoeberl 2009



Shin 2009




Typical Parameter Values

Table 2. Parameters ar	d Their T	Sypical V	Values ^a
------------------------	-----------	-----------	---------------------

parameter	description	value	units
п	cell density	3.3×10^{4}	cells/mL
L_0	initial ligand concentration	$k_{\rm f}/k_{\rm f}$	M
R_0	initial number of free receptors	10 ⁵	no./cell
A_1^T , A_2^T	total number of each adaptor protein	10^{4}	no./cell
E_i^{T} , $i = 1-5$	total number of activating enzymes at stage i	10^{4}	no./cell
$P_i^{\mathrm{T}}, i = 1-5$	total number of deactivating enzymes at each stage i	5×10^{3}	no./cell
$k_{\rm f}$	receptor-ligand association rate constant	10^{7}	M^{-1} min ⁻¹
k_r	receptor-ligand dissociation rate constant	0.3	min ⁻¹
k _c	rate constant for dimerization of ligand-bound receptors	6×10^{7}	M^{-1} min ⁻¹
k _u	rate constant for dissociation of dimers	60	min ⁻¹
k_c^+ k_c^-	rate constant for activation of dimerized receptor—ligand complexes	50	min^{-1}
k_c^-	rate constant for deactivation of active receptor—ligand dimers	5	min^{-1}
k_f^1 , k_f^2 , k_f^{12} , k_c^{12}	association rate constants among adaptors	3×10^{8}	M^{-1} min ⁻¹
k_r^{1/k_f^1} , k_r^{2/k_f^2} , $k_r^{12/k_f^{12}}$, $k_d^{12/k_H^{12}}$	equilibrium dissociation constant for adaptor interactions	10^{-7}	M
$k_1^+, k_2^+, k_2^+, k_2^+$	enzyme-substrate association rate constant	6×10^{8}	$M^{-1} min^{-1}$
$k_{I}^{-}, k_{P_{I}^{-}}, k_{x}^{-}, k_{z}^{-}$	enzyme-substrate dissociation rate constant	30	min^{-1}
$k_{\text{cat},l}, k_{\text{cat},P_l}, k_{\text{cat},x}, k_{\text{cat},z}$	rate constant for the formation of product from enzyme-substrate transition complex	6	min ⁻¹

My Model(s)

- 1. Primary goal: account for dimerization, better understand the role of KSR
- 2. Primary premise: scaffolds (i.e. KSR or RAS) serve as a platform to induce/stabilize dimerization
- 3. Assumptions: a) scaffold itself is dimeric
 - b) RAF dimers protect protomers from dephosphorylation
 - c) RAF monomers are rapidly dephosphorylated
- 4. Variations of the model:
 - a) RAS is the actual platform for RAF assembly
 - b) KSR dimers may serve to sustain dimer population in the cytoplasm
 - c) various modification of association rules



BioNetGen

1. Rules:

$$X(a,b) + Y(c,d) <-> X(a!1,b).Y(c!1,d) kf1,kr1$$

 $Y(d) + Z() -> Y(d^P) + Z() kf2$

- 2. Emphasis on Domain Structure and Interactions
- 3. Combinatorial Complexity